Skip over navigation
The Hospital
Research
Support Us
Ottawa Hospital Research Institute
Home
Français
Directions & Maps
Contact Us
About Us
Vision and Strategic Directions
Board Chair and CEO Message
Leadership Team
Annual Reports
Facilities
Research Data Management
Equity, Diversity and Inclusion
Wellness
Our Research
Priorities, Programs and Diseases
Researcher Profiles
National Research Networks
Scientific Publications
Research Awards
Technology Transfer
Industry Sponsored Research
Responsible Innovation
For Students & Fellows
News & Events
Newsroom
Seminars & Events
Career Opportunities
For Patients
News & Events
Home
>
News & Events
>
Newsroom
Bookmark or Share
Display Options
Display Options
+
Increase
/
-
Decrease
font size
High contrast version
Printer-friendly version
Newsroom
Seminars & Events
Newsroom
New research sheds light on possible anti-cancer activity of FAK inhibitors
October 26, 2011
New research led by
Dr. Christina Addison
suggests that a class of experimental anti-cancer compounds commonly thought to only target tumour cells directly, may in fact also be targeting the blood vessels that feed tumours. Dr. Addison’s research shows that the compounds, known as FAK inhibitors, are approximately 20 times more potent in preventing blood vessel growth than they are in preventing cancer growth. With a better understanding of how these compounds work, it may now be possible to develop ways to enhance their anti-tumour activity, perhaps by combining them with complementary cancer drugs. See
Molecular Oncology
for details.
This research was supported by the Canadian Institutes of Health Research and the Canadian Breast Cancer Foundation. All research at OHRI is also supported by The Ottawa Hospital Foundation.